Roivant recently sold one spinout for billions. Is Priovant next?

Max Bayer

Pharma Reporter

When Roivant announced positive Phase 2 data of a key inflammatory drug back in April, the CEO of Priovant — the subsidiary in charge of development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Roivant recently sold one spinout for billions. Is Priovant next?

Max Bayer

Pharma Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Exclusive: Influential Democrat will oppose Biosecure Act ahead of House vote

Astellas CEO talks future beyond Xtandi as Japanese drugmaker puts roots in Boston

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Roche's Spark loses CEO to RNA upstart; Ex-Elevation Oncology chief takes over at Affimed

Lilly inks obesity deal with seed-stage RNA startup as its genetic medicines effort enters the spotlight

How to secure full enrollment and a 30x ROI: A conversation with the CEO of the boutique enrollment agency doing just ...

Roivant re­cent­ly sold one spin­out for bil­lions. Is Pri­o­vant next?

Pharma Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Roivant recently sold one spinout for billions. Is Priovant next?